McKechnie Buys 60,000 ACM Research Shares at 46% Discount, Amid Insider Sell‑Offs — A Cautiously Optimistic Signal for Investors

Insider Activity at ACM Research Inc. – What the Latest Transactions Mean for Investors

A Quiet Buy Amid Heavy Selling

On March 12, 2026, director and officer Mark McKechnie purchased 60 000 shares of ACM Research’s Class A common stock at $13.89, raising his holdings to 60 900 shares. This buy comes at a price that is roughly 46 % below the current market close of $45.27, indicating a deep discount relative to the share’s recent 52‑week high of $71.65. The same day, McKechnie sold 11 910 shares at an average of $44.89, and a further 47 108 shares at $45.74, reflecting a pattern of selling as the price approached the upper mid‑range of the daily spread. The total net position after all trades on that day is an increase of 5 900 shares, suggesting that McKechnie is accumulating shares while still taking profits from a large block of holdings.

Implications for the Share Price and Market Sentiment

The buy was made under a Rule 10b‑5‑1 trading plan that McKechnie adopted in August 2025, a standard mechanism for insiders to avoid “insider‑trading” pitfalls. Because the purchase price is substantially below the current market level, it may signal confidence in ACM Research’s long‑term prospects, especially given the company’s strong position in wet‑processing equipment and its recent expansion into wafer‑level packaging solutions. The concurrent selling, however, indicates a disciplined approach to liquidity management and risk reduction. For investors, the net increase of 5 900 shares—while modest relative to the company’s outstanding shares—can be viewed as a positive endorsement, especially when contrasted with the heavy selling seen from other insiders (e.g., Hui Wang and Tracy Liu) earlier in March.

A Look at McKechnie’s Trading History

McKechnie’s transaction history in the past year shows a consistent pattern of buying at lower price points and selling near the current market level. In December 2025, he bought 22 500 shares at $25.45 and sold 22 500 shares at $35.45 in a single day, netting a gain of $10 per share. He also exercised 22 500 options at zero cost and sold the resulting shares. In early December, he bought 8 750 shares at $4.55—a significant discount to the market price—while later selling 7 754 shares at $33.50. These moves suggest that McKechnie prefers to lock in gains early and is comfortable with sizable block trades under Rule 144 or Rule 10b‑5‑1 plans. His recent purchase at $13.89 follows the same logic: he is willing to pay a premium only when the price trend signals a potential upside.

How This Fits Into Company‑Wide Insider Activity

Across the board, insider transactions in March 2026 show a mix of buying and selling. Hui Wang’s 60 000‑share purchase and sale, Tracy Liu’s 15 000‑option exercise followed by a 45 000‑share sale, and Dun Haiping’s option acquisition and subsequent 4 100‑share sale all indicate a pattern of short‑term liquidity needs or personal portfolio balancing. McKechnie’s purchase, by contrast, appears to be a longer‑term stake‑building move. With the company’s market cap hovering around $2.75 billion and a P/E of 40.78, the share price still has room to grow, especially if ACM Research successfully monetizes its wet‑processing technologies amid increasing demand for advanced semiconductor manufacturing.

Takeaway for Investors

• Positive signal: McKechnie’s net increase of 5 900 shares, purchased at a deep discount, reflects confidence in the company’s fundamentals.
• Balanced approach: The simultaneous sales suggest prudent risk management and liquidity planning.
• Historical consistency: McKechnie’s trading pattern aligns with a disciplined, long‑term investment philosophy.
• Company context: Amid broader insider selling, McKechnie’s buy stands out, potentially offering a “buy the dip” opportunity for investors who believe in ACM Research’s technology pipeline.

Overall, the transaction paints a cautiously optimistic picture for ACM Research. While insider selling may raise short‑term concerns, McKechnie’s disciplined accumulation of shares at attractive prices provides a counterweight that could bode well for the stock’s trajectory in the coming quarters.